This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

EDAP Successfully Completes Preliminary Trial Of HIFU In Liver Cancer

LYON, France, Oct. 26, 2010 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, reported today successful completion of the first phase of the clinical protocol aimed at evaluating High Intensity Focused Ultrasound (HIFU) technology in patients with metastatic liver cancer. HIFU has the potential to destroy liver tumors through ablation and to reduce bleeding during surgery.

In an initial preliminary protocol phase, six patients were successfully treated using a newly-developed HIFU tool delivering focused ultrasound to cancerous liver tumors. Clinical results observed fully conformed with those obtained in pre-clinical studies and validated HIFU as being an additional potential option to address liver cancer. More studies need to be implemented and EDAP, together with the clinical team from Lyon-based Centre Leon Berard and INSERM U556, will enter into a second clinical phase that will include a larger number of patients. This study is designed to further validate the performance of this new HIFU instrument in the treatment of liver cancer.

Pr. Michel Rivoire, Head of Digestive Cancer Surgery Department at Centre Leon Berard, Lyon, commented, "The initial phase of this clinical trial allowed us to confirm safety and efficacy of this new powerful device. All our clinical hypotheses have been confirmed and we were pleased to make these preliminary assessments in less than six months. After validation of these results by an external independent committee, we will begin the second phase of this trial that will be designed to demonstrate the ability and precision of this new tool to fully destroy liver tumors without inducing damage to normal surrounding liver parenchyma."

Marc Oczachowski, EDAP Chief Executive Officer, added, "We are very pleased with the performance of our HIFU technology in this early stage study addressing liver cancer. Our expertise in focused ultrasound, together with the close and long term relationship we have with INSERM in developing HIFU technology, should help in advancing future therapies. In the meantime, we remain fully focused on expanding the Ablatherm-HIFU activity for patients with localized prostate cancer."

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,943.81 +28.74 0.17%
S&P 500 1,967.57 +2.89 0.15%
NASDAQ 4,415.49 +19.2860 0.44%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs